According to a PharmaTimes report, the EC has confirmed that bevacizumab in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in the EU, following an investigation into the drug's benefit-risk profile. However, the Commission agreed with a recommendation from the Committee for Medicinal Products for Human Use to remove use in combination with docetaxel for the first-line treatment of metastatic breast cancer from the drug's product license. The decision is in contrast to that in the US where the FDA is considering withdrawing the breast cancer indications. Roche and US partner Genentech have won a hearing in the US to plead the case in support of bevacizumab, which is scheduled for the end of June 2011.